Creabilis appoints new chief executive
Eliot Forster brings significant drug development experience to firm
Forster brings almost 20 years’ industry experience in biotechnology and pharmaceutical companies to the Luxembourg-based firm.
He was most recently chief executive of Solace Pharmaceuticals, a US-based biotech. Prior to this, was Pfizer’s head of EU development and of development operations in the EU and Asia. During his career at Pfizer Forster was integral to bringing a number of drugs to market, including Celebrex (celecoxib), Bextra (valcecoxib) and Relpax (eletriptan).
Creabilis’ lead product is CT327, a novel topically applied TrkA kinase inhibitor developed using the Company’s LSE (Low Systemic Exposure) technology. It is currently in Phase II clinical trials in psoriasis and atopic dermatitis.
The Creabilis portfolio also includes CT637, a new approach to the treatment of significant inflammatory conditions such as rheumatoid arthritis as well as severe psoriasis.
You may also like
Drug Delivery
Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody
The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Research & Development
FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design
The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline
Research & Development
Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive
Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage
Research & Development
Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic
Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform
Research & Development
Early stage clinical trials highlight the convergence of novel therapeutics and enabling technologies
Early stage clinical development is increasingly being shaped by advances in drug discovery and the technologies and manufacturing strategies that enable the safe, precise and scalable delivery of new therapies
Research & Development
Breast cancer is the world’s most studied disease for fifth consecutive year according to analysis from Phesi
The US led global clinical trial activity in 2025 and across all top five indications, with China recording the fastest growth in the number of recruiting clinical trial sites